{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:00:39Z","timestamp":1792231239256,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Girls affected with Turner syndrome (TS) present with low bone mineral density (BMD) and osteopenia\/osteoporosis. Thus, they have an increased risk to develop fractures compared to normal population. The aim of this study was to deepen the pathophysiology of skeletal fragility in TS subjects by evaluating the serum levels of Dickkopf-1 (DKK-1) and sclerostin, main regulators of bone mass, as well as the percentage of circulating osteoblast precursors (OCPs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirty-four TS girls and 24 controls were recruited. All subjects underwent anthropometric measures (height, weight, body mass index-BMI). A peripheral venous blood sample was collected to determine serum levels of active intact parathyroid hormone (PTH), 25-OH vitamin D, calcium, phosphorus, bone alkaline phosphatase (bALP), osteocalcin, sclerostin, DKK-1, RANKL and OPG. OCPs were detected by flow cytometry. In TS subjects bone mineralization was measured at lumbar spine by dual energy X-ray absorptiometry (DXA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>bALP, 25-OH Vitamin D, and osteocalcin levels were significant lower in TS subjects than in the controls. Statistically significant higher levels of sclerostin, DKK-1 and RANKL were measured in patients compared with the controls. The percentage of OCPs did not show significant differences between patients and controls. Sclerostin and DKK-1 levels were related with anthropometric parameters, bone metabolism markers, HRT, rhGH therapy, RANKL and lumbar BMAD-Z-score.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>TS patients showed higher levels of sclerostin and DKK-1 than controls which can be related to HRT, and to reduced bone formation markers as well as the increased bone resorption activity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-022-01760-3","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T18:02:31Z","timestamp":1646244151000},"page":"1255-1263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome"],"prefix":"10.1007","volume":"45","author":[{"given":"M.","family":"Chiarito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Piacente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Chaoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pontrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"D\u2019Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Grandone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Street","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Wasniewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1899-8337","authenticated-orcid":false,"given":"M. F.","family":"Faienza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"1760_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ajmg.c.31683","volume":"181","author":"M Viuff","year":"2019","unstructured":"Viuff M, Skakkeb\u00e6k A, Nielsen MM et al (2019) Epigenetics and genomics in Turner syndrome. Am J Med Genet 181:125\u2013132. https:\/\/doi.org\/10.1002\/ajmg.c.31683","journal-title":"Am J Med Genet"},{"key":"1760_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fendo.2016.00034","volume":"7","author":"MF Faienza","year":"2016","unstructured":"Faienza MF, Ventura A, Colucci S et al (2016) Bone fragility in Turner syndrome: mechanisms and prevention strategies. Front Endocrinol 7:34. https:\/\/doi.org\/10.3389\/fendo.2016.00034","journal-title":"Front Endocrinol"},{"key":"1760_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11154-008-9076-2","volume":"9","author":"VK Bakalov","year":"2008","unstructured":"Bakalov VK, Bondy CA (2008) Fracture risk and bone mineral density in Turner syndrome. Rev Endocr Metab Disord 9:145\u2013151. https:\/\/doi.org\/10.1007\/s11154-008-9076-2","journal-title":"Rev Endocr Metab Disord"},{"key":"1760_CR4","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1210\/jc.2003-030913","volume":"88","author":"VK Bakalov","year":"2003","unstructured":"Bakalov VK, Axelrod L, Baron J et al (2003) Selective reduction in cortical bone mineral density in Turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab 88:5717\u20135722. https:\/\/doi.org\/10.1210\/jc.2003-030913","journal-title":"J Clin Endocrinol Metab"},{"key":"1760_CR5","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00198-010-1170-0","volume":"21","author":"CR Holroyd","year":"2010","unstructured":"Holroyd CR, Davies JH, Taylor P et al (2010) Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome. Osteoporos Int 21:2093\u20132099. https:\/\/doi.org\/10.1007\/s00198-010-1170-0","journal-title":"Osteoporos Int"},{"key":"1760_CR6","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1172\/JCI28551","volume":"116","author":"V Krishnan","year":"2006","unstructured":"Krishnan V (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116:1202\u20131209. https:\/\/doi.org\/10.1172\/JCI28551","journal-title":"J Clin Invest"},{"key":"1760_CR7","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.3892\/mmr.2015.3152","volume":"11","author":"W Liu","year":"2015","unstructured":"Liu W, Zhang X (2015) Receptor activator of nuclear factor-\u03baB ligand (RANKL)\/RANK\/osteoprotegerin system in bone and other tissues. Mol Med Rep 11:3212\u20133218. https:\/\/doi.org\/10.3892\/mmr.2015.3152","journal-title":"Mol Med Rep"},{"key":"1760_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/17446651.2020.1834846","volume":"15","author":"M Chiarito","year":"2020","unstructured":"Chiarito M, Brunetti G, D\u2019Amato G, Faienza MF (2020) Monitoring and maintaining bone health in patients with Turner syndrome. Expert Rev Endocrinol Metab 15:431\u2013438. https:\/\/doi.org\/10.1080\/17446651.2020.1834846","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1760_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s12020-014-0513-6","volume":"50","author":"T Aversa","year":"2015","unstructured":"Aversa T, Messina MF, Mazzanti L et al (2015) The association with Turner syndrome significantly affects the course of Hashimoto\u2019s thyroiditis in children, irrespective of karyotype. Endocrine 50:777\u2013782. https:\/\/doi.org\/10.1007\/s12020-014-0513-6","journal-title":"Endocrine"},{"key":"1760_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.14310\/horm.2002.1574","volume":"14","author":"T Aversa","year":"2015","unstructured":"Aversa T, Salerno M, Radetti G et al (2015) Peculiarities of presentation and evolution over time of Hashimoto\u2019s thyroiditis in children and adolescents with Down\u2019s syndrome. Hormones (Athens) 14:410\u2013416. https:\/\/doi.org\/10.14310\/horm.2002.1574","journal-title":"Hormones (Athens)"},{"key":"1760_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.bone.2015.07.021","volume":"81","author":"MF Faienza","year":"2015","unstructured":"Faienza MF, Brunetti G, Ventura A et al (2015) Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner\u2019s syndrome. Bone 81:228\u2013236. https:\/\/doi.org\/10.1016\/j.bone.2015.07.021","journal-title":"Bone"},{"key":"1760_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.3074","volume":"19","author":"R Baron","year":"2013","unstructured":"Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19:179\u2013192. https:\/\/doi.org\/10.1038\/nm.3074","journal-title":"Nat Med"},{"key":"1760_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12519-018-0198-7","volume":"15","author":"G Brunetti","year":"2019","unstructured":"Brunetti G, D\u2019Amato G, Chiarito M et al (2019) An update on the role of RANKL\u2013RANK\/osteoprotegerin and WNT-\u00df-catenin signaling pathways in pediatric diseases. World J Pediatr 15:4\u201311. https:\/\/doi.org\/10.1007\/s12519-018-0198-7","journal-title":"World J Pediatr"},{"key":"1760_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156\u2013163. https:\/\/doi.org\/10.1038\/nm1538","journal-title":"Nat Med"},{"key":"1760_CR15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJM200508183530719","volume":"353","author":"M Sata","year":"2005","unstructured":"Sata M, Tanaka K, Nagai R (2005) Circulating osteoblast-lineage cells. New Engl J Med 353:737\u2013738. https:\/\/doi.org\/10.1056\/NEJM200508183530719","journal-title":"New Engl J Med"},{"key":"1760_CR16","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.bone.2006.12.064","volume":"40","author":"GZ Eghbali-Fatourechi","year":"2007","unstructured":"Eghbali-Fatourechi GZ, M\u00f6dder UIL, Charatcharoenwitthaya N et al (2007) Characterization of circulating osteoblast lineage cells in humans. Bone 40:1370\u20131377. https:\/\/doi.org\/10.1016\/j.bone.2006.12.064","journal-title":"Bone"},{"key":"1760_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00198-009-0968-0","volume":"21","author":"M Pirro","year":"2010","unstructured":"Pirro M, Leli C, Fabbriciani G et al (2010) Association between circulating osteoprogenitor cell numbers and bone mineral density in postmenopausal osteoporosis. Osteoporos Int 21:297\u2013306. https:\/\/doi.org\/10.1007\/s00198-009-0968-0","journal-title":"Osteoporos Int"},{"key":"1760_CR18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s00198-011-1666-2","volume":"23","author":"P D\u2019Amelio","year":"2012","unstructured":"D\u2019Amelio P, Tamone C, Sassi F et al (2012) Teriparatide increases the maturation of circulating osteoblast precursors. Osteoporos Int 23:1245\u20131253. https:\/\/doi.org\/10.1007\/s00198-011-1666-2","journal-title":"Osteoporos Int"},{"key":"1760_CR19","unstructured":"http:\/\/www.weboriented.it\/gh4\/"},{"key":"1760_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/adc.51.3.170","volume":"51","author":"JM Tanner","year":"1976","unstructured":"Tanner JM, Whitehouse RH (1976) Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 51:170\u2013179. https:\/\/doi.org\/10.1136\/adc.51.3.170","journal-title":"Arch Dis Child"},{"key":"1760_CR21","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0430","volume":"177","author":"Gravholt CH, Andersen NH, Conway GS, et al; International Turner Syndrome Consensus Group","year":"2017","unstructured":"Gravholt CH, Andersen NH, Conway GS, et al; International Turner Syndrome Consensus Group (2017) Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner syndrome meeting. Eur J Endocrinol 177:G1\u2013G70. https:\/\/doi.org\/10.1530\/EJE-17-0430","journal-title":"Eur J Endocrinol"},{"key":"1760_CR22","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/BF03345738","volume":"32","author":"S Bertelloni","year":"2009","unstructured":"Bertelloni S, Balsamo A, Giordani L et al (2009) 17beta-hydroxysteroid dehydrogenase-3 deficiency: from pregnancy to adolescence. J Endocrinol Invest 32:666\u2013670. https:\/\/doi.org\/10.1007\/BF03345738","journal-title":"J Endocrinol Invest"},{"key":"1760_CR23","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1210\/jc.2005-1081","volume":"90","author":"RL Rosenfield","year":"2005","unstructured":"Rosenfield RL, Devine N, Hunold JJ et al (2005) Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab 90:6424\u20136430. https:\/\/doi.org\/10.1210\/jc.2005-1081","journal-title":"J Clin Endocrinol Metab"},{"key":"1760_CR24","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1056\/NEJMoa1005669","volume":"364","author":"JL Ross","year":"2011","unstructured":"Ross JL, Quigley CA, Cao D et al (2011) Growth hormone plus childhood low-dose estrogen in Turner\u2019s syndrome. N Engl J Med 364:1230\u20131242. https:\/\/doi.org\/10.1056\/NEJMoa1005669","journal-title":"N Engl J Med"},{"key":"1760_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1530\/EJE-12-0444","volume":"167","author":"JI Labarta","year":"2012","unstructured":"Labarta JI, Moreno ML, L\u00f3pez-Siguero JP et al (2012) Individualised vs fixed dose of oral 17\u03b2-oestradiol for induction of puberty in girls with Turner syndrome: an open-randomised parallel trial. Eur J Endocrinol 167:523\u2013529. https:\/\/doi.org\/10.1530\/EJE-12-0444","journal-title":"Eur J Endocrinol"},{"key":"1760_CR26","doi-asserted-by":"publisher","first-page":"E1754","DOI":"10.1210\/jc.2013-4518","volume":"99","author":"CA Quigley","year":"2014","unstructured":"Quigley CA, Wan X, Garg S et al (2014) Effects of low-dose estrogen replacement during childhood on pubertal development and gonadotropin concentrations in patients with Turner syndrome: results of a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 99:E1754\u2013E1764. https:\/\/doi.org\/10.1210\/jc.2013-4518","journal-title":"J Clin Endocrinol Metab"},{"key":"1760_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1507\/endocrj.EJ11-0267","volume":"59","author":"M Kodama","year":"2012","unstructured":"Kodama M, Komura H, Kodama T et al (2012) Estrogen therapy initiated at an early age increases bone mineral density in Turner syndrome patients. Endocr J 59:153\u2013159. https:\/\/doi.org\/10.1507\/endocrj.EJ11-0267","journal-title":"Endocr J"},{"key":"1760_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/cen.14484","volume":"95","author":"S Nishigaki","year":"2021","unstructured":"Nishigaki S, Itonaga T, Hasegawa Y, Kawai M (2021) Starting age of oestrogen-progestin therapy is negatively associated with bone mineral density in young adults with Turner syndrome independent of age and body mass index. Clin Endocrinol 95:84\u201391. https:\/\/doi.org\/10.1111\/cen.14484","journal-title":"Clin Endocrinol"},{"key":"1760_CR29","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.orcp.2015.08.016","volume":"10","author":"H Lu","year":"2016","unstructured":"Lu H, Li X, Mu P et al (2016) Dickkopf-1 promotes the differentiation and adipocytokines secretion via canonical Wnt signaling pathway in primary cultured human preadipocytes. Obes Res Clin Pract 10:454\u2013464. https:\/\/doi.org\/10.1016\/j.orcp.2015.08.016","journal-title":"Obes Res Clin Pract"},{"key":"1760_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003627","volume":"3","author":"I Roato","year":"2008","unstructured":"Roato I, D\u2019Amelio P, Gorassini E et al (2008) Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS\u00a0One 3:e3627. https:\/\/doi.org\/10.1371\/journal.pone.0003627","journal-title":"PLoS\u00a0One"},{"key":"1760_CR31","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/sj.bjc.6604069","volume":"97","author":"N Lee","year":"2007","unstructured":"Lee N, Smolarz AJ, Olson S et al (2007) A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer 97:1552\u20131559. https:\/\/doi.org\/10.1038\/sj.bjc.6604069","journal-title":"Br J Cancer"},{"key":"1760_CR32","doi-asserted-by":"publisher","first-page":"E546","DOI":"10.1152\/ajpendo.00535.2012","volume":"304","author":"G Brunetti","year":"2013","unstructured":"Brunetti G, Faienza MF, Piacente L et al (2013) High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment. Am J Physiol Endocrinol Metab 304:E546\u2013E554. https:\/\/doi.org\/10.1152\/ajpendo.00535.2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1760_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1476-4598-6-71","volume":"6","author":"K Fujita","year":"2007","unstructured":"Fujita K, Janz S (2007) Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG. RANKL and M-CSF Mol Cancer 6:71. https:\/\/doi.org\/10.1186\/1476-4598-6-71","journal-title":"RANKL and M-CSF Mol Cancer"},{"key":"1760_CR34","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1038\/bcj.2011.22","volume":"1","author":"S Colucci","year":"2011","unstructured":"Colucci S, Brunetti G, Oranger A et al (2011) Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J 1:e27\u2013e27. https:\/\/doi.org\/10.1038\/bcj.2011.22","journal-title":"Blood Cancer J"},{"key":"1760_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13075-021-02562-3","volume":"23","author":"A Corrado","year":"2021","unstructured":"Corrado A, Rotondo C, Mele A et al (2021) Influence of glucocorticoid treatment on trabecular bone score and bone remodeling regulators in early rheumatoid arthritis. Arthritis Res Ther 23:180. https:\/\/doi.org\/10.1186\/s13075-021-02562-3","journal-title":"Arthritis Res Ther"},{"key":"1760_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/235060","volume":"2014","author":"V Locatelli","year":"2014","unstructured":"Locatelli V, Bianchi VE (2014) Effect of GH\/IGF-1 on bone metabolism and osteoporosis. Int J Endocrinol 2014:1\u201325. https:\/\/doi.org\/10.1155\/2014\/235060","journal-title":"Int J Endocrinol"},{"key":"1760_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/1479-5876-11-271","volume":"11","author":"L Guerra-Men\u00e9ndez","year":"2013","unstructured":"Guerra-Men\u00e9ndez L, S\u00e1daba MC, Puche JE et al (2013) IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand. J Transl Med 11:271. https:\/\/doi.org\/10.1186\/1479-5876-11-271","journal-title":"J Transl Med"},{"key":"1760_CR38","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ebiom.2018.11.051","volume":"39","author":"J Feehan","year":"2019","unstructured":"Feehan J, Nurgali K, Apostolopoulos V et al (2019) Circulating osteogenic precursor cells: Building bone from blood. EBioMedicine 39:603\u2013611. https:\/\/doi.org\/10.1016\/j.ebiom.2018.11.051","journal-title":"EBioMedicine"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01760-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-01760-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01760-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T17:08:39Z","timestamp":1658768919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-01760-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1760"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-01760-3","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,2]]},"assertion":[{"value":"21 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The clinical investigations were in accordance with the ethical standards of the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the subjects before any clinical procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}